Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
11.01 USD | +14.09% | +10.95% | 0.00% |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2021 | 2022 | 2023 |
---|---|---|---|
Net sales 1 | 3.465 | 0.5915 | 3.154 |
EBITDA 1 | -1.598 | -2.209 | -3.039 |
EBIT 1 | -1.632 | -2.27 | -3.128 |
Operating Margin | -47.09% | -383.83% | -99.18% |
Earnings before Tax (EBT) 1 | -1.265 | -2.682 | 5.27 |
Net income 1 | -1.265 | -2.682 | 5.27 |
Net margin | -36.5% | -453.44% | 167.11% |
EPS 2 | -0.5900 | -1.250 | 1.455 |
Free Cash Flow | - | -1.218 | -1.825 |
FCF margin | - | -205.91% | -57.87% |
FCF Conversion (EBITDA) | - | - | - |
FCF Conversion (Net income) | - | - | - |
Dividend per Share | - | - | - |
Announcement Date | 23-11-14 | 23-11-14 | 24-04-01 |
Balance Sheet Analysis
Fiscal Period: December | 2021 | 2022 | 2023 |
---|---|---|---|
Net Debt 1 | - | 1.28 | - |
Net Cash position 1 | 0.91 | - | 3.92 |
Leverage (Debt/EBITDA) | - | -0.5778 x | - |
Free Cash Flow | - | -1.22 | -1.82 |
ROE (net income / shareholders' equity) | - | 268% | 594% |
ROA (Net income/ Total Assets) | - | -105% | -39.8% |
Assets 1 | - | 2.554 | -13.24 |
Book Value Per Share 2 | -16.40 | -17.00 | -13.10 |
Cash Flow per Share 2 | 0.1500 | 0.2400 | 3.090 |
Capex 1 | 0.08 | 0.01 | 0.5 |
Capex / Sales | 2.45% | 1.64% | 15.98% |
Announcement Date | 23-11-14 | 23-11-14 | 24-04-01 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
0.00% | 84.84M | |
+18.10% | 124B | |
+18.03% | 111B | |
-12.59% | 23.17B | |
+5.07% | 22.94B | |
-39.94% | 17.42B | |
-9.68% | 17.42B | |
-14.97% | 16.9B | |
+2.72% | 13.71B | |
+27.35% | 11.82B |
- Stock Market
- Equities
- AGE Stock
- Financials Serina Therapeutics, Inc.